Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results67% success

Data Visualizations

Phase Distribution

4Total

P 2 (3)

P 4 (1)

Trial Status

Recruiting3

Completed2

Active Not Recruiting1

Terminated1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT00005902Active Not RecruitingPrimary

Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease

NCT06638931Phase 2Recruiting

Agnostic Therapy in Rare Solid Tumors

NCT05259605Recruiting

Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification

NCT04081701Phase 4Recruiting

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

NCT00330564Phase 2Terminated

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

NCT00970970Completed

Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease

NCT00589784Phase 2Completed

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Showing all 7 trials

Hemangioblastoma